PFIZER2026-07-012026-09-30PFIZER2026-09-30PFIZER2026-03-31PFIZER2026-04-012026-09-30PFIZER2026-07-012026-09-30in-capmkt:OtherExpenses1MemberPFIZER2026-04-012026-09-30in-capmkt:OtherExpenses1MemberPFIZER2026-09-30OtherNoncurrentFinancialAssetsDomain1PFIZER2026-09-30OtherNoncurrentAssetsDomain1PFIZER2026-09-30OtherNoncurrentAssetsDomain2PFIZER2026-09-30OtherCurrentFinancialAssetsDomain1PFIZER2026-09-30OtherCurrentAssetsDomain1PFIZER2026-09-30OtherNoncurrentFinancialLiabilitiesDomain1PFIZER2026-09-30OtherNoncurrentFinancialLiabilitiesDomain2PFIZER2026-09-30OtherCurrentFinancialLiabilitiesDomain1PFIZER2026-09-30OtherCurrentFinancialLiabilitiesDomain2PFIZER2026-09-30OtherCurrentLiabilitiesDomain1PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain1PFIZER2026-06-30RelatedPartyTransactionDomain1PFIZER2026-09-30RelatedPartyTransactionDomain1PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain2PFIZER2026-06-30RelatedPartyTransactionDomain2PFIZER2026-09-30RelatedPartyTransactionDomain2PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain3PFIZER2026-06-30RelatedPartyTransactionDomain3PFIZER2026-09-30RelatedPartyTransactionDomain3PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain4PFIZER2026-06-30RelatedPartyTransactionDomain4PFIZER2026-09-30RelatedPartyTransactionDomain4PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain5PFIZER2026-06-30RelatedPartyTransactionDomain5PFIZER2026-09-30RelatedPartyTransactionDomain5PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain6PFIZER2026-06-30RelatedPartyTransactionDomain6PFIZER2026-09-30RelatedPartyTransactionDomain6PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain7PFIZER2026-06-30RelatedPartyTransactionDomain7PFIZER2026-09-30RelatedPartyTransactionDomain7PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain8PFIZER2026-06-30RelatedPartyTransactionDomain8PFIZER2026-09-30RelatedPartyTransactionDomain8PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain9PFIZER2026-06-30RelatedPartyTransactionDomain9PFIZER2026-09-30RelatedPartyTransactionDomain9PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain10PFIZER2026-06-30RelatedPartyTransactionDomain10PFIZER2026-09-30RelatedPartyTransactionDomain10PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain11PFIZER2026-06-30RelatedPartyTransactionDomain11PFIZER2026-09-30RelatedPartyTransactionDomain11PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain12PFIZER2026-06-30RelatedPartyTransactionDomain12PFIZER2026-09-30RelatedPartyTransactionDomain12PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain13PFIZER2026-06-30RelatedPartyTransactionDomain13PFIZER2026-09-30RelatedPartyTransactionDomain13PFIZER2026-07-012026-09-30RelatedPartyTransactionDomain14PFIZER2026-06-30RelatedPartyTransactionDomain14PFIZER2026-09-30RelatedPartyTransactionDomain14iso4217:INRxbrli:pureiso4217:INRxbrli:shares500680PFIZERNOTLISTEDINE182A01018Pfizer LimitedMain BoardEquity2026-04-012027-03-312026-11-032026-10-26INRCroresQuarterlySecond quarterSingle segmentPharmaceuticals2026-11-0312:00:002026-11-0314:00:00trueCash Flow IndirectNot applicabletruetrueNANAfalsetrue2026-07-28https://www.pfizerltd.co.in/files/Pfizer_Limited_-_Policy_on_Related_Party_Transactions_28_07_2026.pdffalsefalseThe Company has not accepted loans or issued debt securties2026-07-012026-09-30UnauditedStandalone72686000004733000007741900000565100000206280000034480000091430000033500000144100000769600000483420000029077000001320600000422830000010759000001990000010958000000313250000000003132500000-540000031271000004575000001068.4700068.4700001.The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on November 3, 2026. <br /> <br /> 2.The financial results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). <br /> <br /> 3.The financial results for the quarter and six months ended September 30, 2026 have been subject to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerltd.co.in <br /> <br /> 4.Exceptional Items <br /> <br /> a.For the quarter and half year ended September 30, 2026: <br /> i.Consequent to a decision by Pfizer Inc. USA. to discontinue the manufacture of Minipress XL, the Company discontinued the marketing, distribution and sale of Minipress XL with effect from September 7, 2026. In connection with the above, the Company will receive a lump sum payment from Pfizer Inc. USA. The value of the lumpsum payment is non-recurring in nature and accordingly, an amount of Rs. 132.06 crore, net of related expenses have been disclosed as Exceptional item. <br /> <br /> b.For the year ended March 31, 2026: <br /> i.The charge of Rs. 41.73 crore for the year ended March 31,2026 towards personnel separation cost of field force and marketing teams as a result of an exclusive Supply and Marketing Agreement with Cipla Limited for marketing and distribution of four brands of the Company, viz., Corex Dx, Corex LS, Dolonex, and Neksium and also includes personnel separation cost for other support functions. <br /> <br /> ii.Effective 21 November 2025, the Government of India had consolidated several existing labour laws into a unified framework consisting of four Labour Codes, collectively known as the New Labour Codes. The Company carried out an assessment based on the best available information and legal opinion, which has resulted in increase in the provision for employee benefits by Rs.7.43 crore for the year ended March 31, 2026. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted for in accordance with applicable accounting standards. <br /> <br /> <br /> 5.The shareholders in its Annual General Meeting held on July 28, 2026 approved a final dividend of Rs.75 per equity share of Rs. 10 each 750 percent for the financial year ended March 31, 2026. The said dividend was paid on August 4, 2026. <br /> <br /> 6.The Company has only one segment which is Pharmaceuticals. Therefore, disclosure relating to segments is not applicable and accordingly not made. <br /> <br /> 7. The Company does not have any subsidiary company or associate company or joint venture company as at September 30, 2026.2026-04-012026-09-30UnauditedStandalone138003000009217000001472200000016153000003891700000-1332000001735100000481000002867000001603800000904750000056745000001320600000699510000017852000003270000018179000000517720000000005177200000-10800000516640000045750000010113.17000113.170000Other Expenses769600000Other Expenses160380000026747000003148000000527490000093700000000000159100000159100000694000000347300000012684200000441730000002414100000928200000307706000000139060000035503500000032480000040245600000005292980000045750000043396600000438541000004385410000000001697600000169760000052450000000222210000025000000134800000228240000024172000001095600000353780000043100000030250000025823000000685360000000907570000052929800000Other financial assets159100000Other Tax Assets1778700000Other non current assets1694300000Other financial assets1390600000Other current assets324800000Lease Liabilities1651800000Other financial liabilities45800000Lease Liabilities291400000Other financial liabilities804200000Other current liabilities4310000000177400000-63720000000-133050000000025400000000028670000043800000289000000053500000009106000008990000000001814000000-1762700000523240000000016425000000358990000000000000024440000000000000000000000010289000000-812500000-28000000000000000020470000034137000004190000000-3660300000-984000000-984000001026600000928200000720000014400000-1800000-3600000-5400000-10800000Pfizer Limited******Pfizer Service Company BVBA,Belgium******Fellow SubsidiaryPurchase of goods or servicesOn arms length basis and in Ordinary course of business3328900000-788300000-1076500000Pfizer Limited******Pfizer Products India Private Limited******Fellow SubsidiarySale of goods or servicesOn arms length basis and in Ordinary course of business172400000237100000186400000Pfizer Limited******Pfizer Export B.V******Fellow SubsidiarySale of goods or servicesOn arms length basis and in Ordinary course of business150000001280000027700000Pfizer Limited******Pfizer Worldwide Service Company******Fellow SubsidiarySale of goods or servicesOn arms length basis and in Ordinary course of business411400000141400000199800000Pfizer Limited******Pfizer Healthcare India Private Limited******Fellow SubsidiarySale of goods or servicesOn arms length basis and in Ordinary course of business364000008520000040200000Pfizer Limited******Pfizer Healthcare India Private Limited******Fellow SubsidiaryAny other transactionRent ExpenseOn arms length basis and in Ordinary course of business2100000-5500000-1100000Pfizer Limited******Pfizer Products India Private Limited******Fellow SubsidiaryAny other transactionEmployee Liability transferred to fellow subsidiaryOn arms length basis and in Ordinary course of business25900000-41300000-25900000Pfizer Limited******Pfizer Healthcare India Private Limited******Fellow SubsidiaryAny other transactionAsset transferred from fellow subsidiaryOn arms length basis and in Ordinary course of business5000000-500000Pfizer Limited******Pfizer Products India Private Limited******Fellow SubsidiaryAny other transactionEmployee Liability transferred from fellow subsidiaryOn arms length basis and in Ordinary course of business340000003500000Pfizer Limited******Pfizer Inc******Ultimate holding companyAny other transactionLumpsum amount for discontinuance of Minipress and recovery of incidental expensesOn arms length basis and not in ordinary course of business134300000001343000000Pfizer Limited******John Wyeth & Brother Limited, UK******Companies exercising significant influenceAny other transactionBorrowingsOn arms length basis and in Ordinary course of business0-25000000-25000000Pfizer Limited******Warner - Lambert Company, LLC, USA******Companies exercising significant influenceAny other transactionrecovery of expenseOn arms length basis and in Ordinary course of business003600000Pfizer Limited******Pfizer Inc******Ultimate holding companyAny other transactionrecovery of expenseOn arms length basis and in Ordinary course of business038000000Pfizer Limited******John Wyeth & Brother Limited, UK******Companies exercising significant influenceAny other transactionrecovery of expenseOn arms length basis and in Ordinary course of business030000005339000000